Brown Advisory’s AbbVie ABBV Stock Holding History

Brown Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$190M	Sell	874,731 -212	-0%	-$47K	0.31%	70
2025 Q4	$200M	Sell	874,943 -7,722	-0.9%	-$1.76M	0.28%	72
2025 Q3	$204M	Buy	882,665 +14,017	+2%	+$2.85M	0.27%	74
2025 Q2	$161M	Buy	868,648 +29,995	+4%	+$5.57M	0.21%	80
2025 Q1	$176M	Sell	838,653 -2,007	-0.2%	-$390K	0.25%	74
2024 Q4	$149M	Buy	840,660 +20,150	+2%	+$3.7M	0.19%	92
2024 Q3	$162M	Sell	820,510 -24,614	-3%	-$4.59M	0.2%	85
2024 Q2	$145M	Buy	845,124 +28,278	+3%	+$4.68M	0.19%	92
2024 Q1	$149M	Sell	816,846 -19,530	-2%	-$3.37M	0.2%	96
2023 Q4	$130M	Buy	836,376 +2,323	+0.3%	+$339K	0.18%	96
2023 Q3	$124M	Sell	834,053 -11,073	-1%	-$1.63M	0.2%	96
2023 Q2	$114M	Sell	845,126 -15,057	-2%	-$2.21M	0.18%	109
2023 Q1	$137M	Buy	860,183 +4,512	+0.5%	+$690K	0.23%	96
2022 Q4	$138M	Sell	855,671 -5,092	-0.6%	-$781K	0.26%	93
2022 Q3	$116M	Buy	860,763 +20,511	+2%	+$2.94M	0.22%	92
2022 Q2	$129M	Buy	840,252 +7,077	+0.8%	+$1.08M	0.24%	93
2022 Q1	$135M	Sell	833,175 -13,122	-2%	-$1.91M	0.2%	97
2021 Q4	$115M	Buy	846,297 +11,427	+1%	+$1.35M	0.14%	112
2021 Q3	$90.1M	Buy	834,870 +51,695	+7%	+$5.91M	0.13%	127
2021 Q2	$88.2M	Buy	783,175 +8,424	+1%	+$949K	0.13%	131
2021 Q1	$83.8M	Sell	774,751 -6,332	-0.8%	-$677K	0.14%	123
2020 Q4	$83.7M	Buy	781,083 +13,366	+2%	+$1.28M	0.15%	117
2020 Q3	$67.2M	Buy	767,717 +126,935	+20%	+$12M	0.14%	114
2020 Q2	$62.9M	Buy	640,782 +14,001	+2%	+$1.23M	0.15%	116
2020 Q1	$47.8M	Buy	626,781 +32,864	+6%	+$2.8M	0.15%	118
2019 Q4	$52.6M	Buy	593,917 +10,333	+2%	+$858K	0.13%	140
2019 Q3	$44.2M	Buy	583,584 +5,696	+1%	+$391K	0.12%	148
2019 Q2	$42M	Sell	577,888 -30,164	-5%	-$2.37M	0.12%	158
2019 Q1	$49M	Sell	608,052 -33,544	-5%	-$2.74M	0.14%	145
2018 Q4	$59.1M	Sell	641,596 -27,274	-4%	-$2.4M	0.2%	92
2018 Q3	$63.3M	Sell	668,870 -5,614	-0.8%	-$532K	0.18%	103
2018 Q2	$62.5M	Sell	674,484 -8,723	-1%	-$852K	0.19%	101
2018 Q1	$64.7M	Sell	683,207 -111,762	-14%	-$12.3M	0.21%	98
2017 Q4	$76.9M	Sell	794,969 -24,810	-3%	-$2.34M	0.24%	88
2017 Q3	$72.8M	Sell	819,779 -6,673	-0.8%	-$508K	0.24%	94
2017 Q2	$59.9M	Sell	826,452 -10,384	-1%	-$698K	0.18%	110
2017 Q1	$54.5M	Buy	836,836 +185	+0%	+$11.6K	0.19%	107
2016 Q4	$52.4M	Sell	836,651 -172,896	-17%	-$10.6M	0.19%	106
2016 Q3	$63.7M	Sell	1,009,547 -36,180	-3%	-$2.34M	0.22%	83
2016 Q2	$64.7M	Sell	1,045,727 -59,177	-5%	-$3.61M	0.23%	81
2016 Q1	$63.1M	Sell	1,104,904 -185,944	-14%	-$10.4M	0.22%	76
2015 Q4	$76.5M	Sell	1,290,848 -56,983	-4%	-$3.28M	0.26%	70
2015 Q3	$73.3M	Buy	1,347,831 +27,922	+2%	+$1.82M	0.26%	69
2015 Q2	$88.7M	Sell	1,319,909 -79,533	-6%	-$5.19M	0.29%	63
2015 Q1	$81.9M	Buy	1,399,442 +742,683	+113%	+$44.9M	0.26%	68
2014 Q4	$43M	Sell	656,759 -62,699	-9%	-$3.95M	0.14%	115
2014 Q3	$41.6M	Sell	719,458 -14,589	-2%	-$810K	0.13%	112
2014 Q2	$41.4M	Buy	734,047 +641	+0.1%	+$33.6K	0.13%	114
2014 Q1	$37.7M	Buy	733,406 +9,540	+1%	+$482K	0.12%	123
2013 Q4	$38.2M	Sell	723,866 -12,879	-2%	-$633K	0.12%	116
2013 Q3	$33M	Buy	736,745 +5,776	+0.8%	+$256K	0.12%	121
2013 Q2	$30.2M	Buy	+730,969	New	+$32M	0.12%	117

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brown Advisory's ABBV Position: Q1 2026 in Review

Brown Advisory reduced its AbbVie (ABBV) stake by 0.02% in Q1 2026, selling an estimated $47K and leaving 874,731 shares worth $190M. The position accounts for 0.31% of the portfolio, ranked #70.

Brown Advisory first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $204M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Brown Advisory held 874,731 shares of AbbVie worth $190M as of Q1 2026.
Brown Advisory sold 212 AbbVie shares in Q1 2026, an estimated $47K.
AbbVie made up 0.31% of Brown Advisory's portfolio in Q1 2026, its #70 holding.
Brown Advisory first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Brown Advisory's AbbVie position peaked at $204M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.